A global epidemic

Diabetes is a disease characterized by abnormally high blood glucose levels. This disease is considered to be one of the major epidemics of the 21st century. Diabetes can cause complications in many parts of the body, increasing the overall risk of premature death (world diabetes report, WHO, 2016).

  • 8.8% of the adult population were affected by diabetes in 2017
  • 629 million diabetics worldwide forecasted for 2045
  • Among diabetics, only 25.3% of men and 36.4% of women monitor their blood glucose (HbA1C <7%)


more than 1

million type 1 diabetics [20-79 years] worldwide in 2017


more than 1099965

children [0-19 years] are affected by this disease


in about 10

percent of these patients, the regulation of glycated hemoglobin levels (> 8%) is poor

Type 1 Diabetes

Auto-immune destruction of pancreatic beta cells producing insulin = insulin dependent

The body no longer produces insulin

5-10% of patients with diabetes

Often diagnosed among children or teenagers

Sudden onset of symptoms

Must inject insulin daily

Type 2 diabetes



  • More than 15 million type 2 diabetics need insulin injection therapy
  • Most type 2 diabetics are diagnosed after the age of 40 years
  • Type 2 diabetes is expected to be the 7th leading cause of death by 2030
  • Body fails to respond to insulin = insulin resistance
  • 90-95% of diabetes patients


  • Often triggered by a number of risk factors: old age, obesity, ooor diet, lack of physical activity, etc.
  • High production of insulin at the beginning of the illness (hyperinsulinemia) followed by a decrease until production stops (pancreatic fatigue)
  • Incidence of the disease is increasing in epidemic proportions
  • Symptoms emerge gradually as the illness progresses

Several phases in the treatment:

  • Change in diet or increase in physical activity
  • Oral anti-diabetics that act according to various mechanisms
  • Insulin injection [=20% of type 2 diabetes patients]

Insulin delivery devices

Diabetics have to measure the amount of glucose in the blood several times a day. Recently, continuous glucose monitoring (CGM) devices have arrived on the market, making it easier to check blood glucose levels while reducing the number of measurements that need to be taken each day. The amount of insulin that the patient has to inject depends on these readings. There are several ways available to them to do this:

Diabetes medical devices comparison

Our products

Defymed is a French SME that develops innovative medical devices aimed at treating patients physiologically in order to improve the clinical effectiveness of their treatment as well as their comfort.

There are currently two medical devices being developed by Defymed which are at an advanced preclinical trial phase:

  • MailPan ®: bioartificial pancreas
  • ExOlin ®: physiological insulin delivery device

The ExOlin® device

The MailPan® device